MPX Bioceutical Corporation (CSE: MPX) (OTC: MPXEF) - Investor Dashboard

MPX Bioceutical Corp
CSE Symbol: MPX
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: 83
Established: 1974
CEO: Scott Boyes

MPX Bioceutical Corporation – Cannabis Operations Portfolio

Current Assets


MPX Bioceutical Corporation provides management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to two medicinal cannabis enterprises in Arizona (3rd under development) operating under the Health for Life brand. It has also developed a high margin wholesale concentrates business, Melting Point Extracts (MPX), which has penetrated about 40% of the market. As a result, MPX Bioceutical Corporation has developed best-in-class operational and commercial practices which can be replicated to future acquisitions. The Health for Life and MPX operations are projected to have generated in excess of $20mm revenue in the year ending 3/31/17, with EBITDA in excess of $6mm.

Arizona: An Attractive Market
  • Medical-only market open since 2012
  • 125K+ patients
  • Liberal 5.1 grams permitted per day
  • Strong barriers to entry with limited number of dispensaries
  • Dispensaries aren’t limited on production or sales


Ownership of 51% of IMT, which owns a 40K sq. ft. cultivation and production facility in Fall River with management services provided to license holder Cannatech Medicinals, which will also be licensed for 3 retail dispensaries (one permitted for Fall River). Massachusetts is a tightly regulated market, where the MPX has first-mover advantage.

Massachusetts: An Attractive Market
  • Cultivation, production and retail dispensary licenses
  • Adult use market expected to grow by CAGR of 113% to US$1B by 2020
  • State regulates number of participants in market

photos coming soon

photos coming soon

Pending Acquisitions


MPX is progressing towards creating one of the largest cannabis enterprises in the U.S., with 10 dispensaries, over 9 million grams per annum of cultivation and over 1.2million grams per annum of high-margin concentrates production. MPX’s acquisition strategy seeks the following: Accretive valuations, Licensed operators with strong operational track record, No turnarounds and Greenfield development in high-potential, early-stage markets with strong barriers to entry.


In addition to the two operational Mesa dispensaries and a third under development in Chino Valley, MPX Bioceutical Corporation is targeting a vertically integrated production, cultivation and retail opportunity that has operational history and is already profitable. The acquisition would include a long-term agreement to provide all managerial and operational services and would allow MPX Bioceutical Corporation to transfer Health for Life’s retail best-practices, to incorporate high-margin MPX products and to implement cultivation optimization practices (press release – 5/17/17)


Three dispensary licenses opportunities (of 109), one production license (of 15 in the state), one supply contract (flower & trim), which are all located within Baltimore, Bethesda area. Maryland is a new market that permits a for-profit business model (press release – 5/17/17)


Ownership of 100% of GreenMart, an operational production and cultivation facility located in Las Vegas and offering MPX extracts and Lucky Kitchen edibles. The facility is capable of producing 1.6mm grams of flower and 85K grams of concentrates per year, and MPX Bioceutical Corporation is also applying for a retail dispensary license.  (press release – 05/04/17)

Visit MPX Bioceutical Corporation,

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. MPX Bioceutical Corporation is a client of NCV Media, LLC. Read our full disclaimer.